Virtual Library
Start Your Search
X. Wang
Author of
-
+
P2.01 - Advanced NSCLC (ID 618)
- Event: WCLC 2017
- Type: Poster Session with Presenters Present
- Track: Advanced NSCLC
- Presentations: 1
- Moderators:
- Coordinates: 10/17/2017, 09:00 - 16:00, Exhibit Hall (Hall B + C)
-
+
P2.01-020 - Continuous Intravenous Infusion Endostar Combined with Pemetrexed plus Cisplatin in Chinese Treatment-Naïve Metastatic Non-Squamous NSCLC (ID 8511)
09:00 - 09:00 | Author(s): X. Wang
- Abstract
Background:
The treatment options of metastatic non-squamous non-small cell lung cancer patient who not harboring abnormal genes are very limited due to the inapplicability of targeting agents. Luckily, recombinant human endostatin (rh-endostatin) as an angiogenetic drug named endostar was approved in treating non-small cell lung cancer (NSCLC) combined with doublet chemotherapy in China. Administration of rh-endostatin is optimized from 3-4 hours intravenous infusion to continuous intravenous infusion in order to improve the compliance. In this study, we observed the efficacy and safety of continuous intravenous infusion rh-endostatin combined with pemetrexed and cisplatin in first-line treatment of non-squamous NSCLC without any gene alternatives.
Method:
The main criteria for patient enrollment includes KPS≥80, stage IV non-squamous histology, EGFR negative, ALK-EML4 negative, ROS1 and MET negative. Forty-six patients were enrolled and received endostar 30mg day1 to day7 continuous intravenous infusion, pemetrexed 500mg/m2 day1, cisplatin 25mg/m2 day1 to day3, 21 days each cycle. All patient received this regimen at least 2 but no more than 6 cycles. The assessment (RECIST 1.1) was applied every 2 cycles during treatment process and then every 3 months afterwards. The primary endpoint is progression free survival (PFS). Secondary endpoints are overall response rate (ORR), disease control rate (DCR) and safety.
Result:
The efficacy of this regimen showed that 2 (4.34%) patients achieving complete response (CR). Nineteen (41.30%) patients have their tumors reach partial response (PR), while 11 (23.91%) patients have a stable disease (SD). The overall response rate was 45.65%. Disease control rate was 69.56%. The median time of progression free survival is 301 (95% CI, 250 – 352) days. Severe adverse events caused by hematological toxicity were rare for this regimen, only 2 cases of myelosuppression were found. The non-hematological side effects, particularly nausea and vomiting were observed in 6 patients during their treatment. There is no severe cardiotoxicity showed related to the regimen used in this trial.
Conclusion:
Continuous intravenous infusion endostar combined with pemetrexed plus cisplatin could be an efficient regimen as a first-line treatment for Chinese patients with metastatic non-squamous NSCLC but without any gene mutants. Patients received this regimen could have a relatively long progression free survival time and well-tolerance.
